For Research Use Only

PLOD2-Specific Polyclonal antibody

Catalog Number:21214-1-AP

Featured Product 50 Publications




Basic Information	Catalog Number: 21214-1-AP	GenBank Accession Number: BC037169 GeneID (NCBI): 5352 UNIPROT ID: O00469		Purification Method: Antigen affinity purification	
	Size:			Recommended Dilutions: WB 1:500-1:3000 IP 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate	
	150ul , Concentration: 500 ug/ml by Nanodrop; Source:				
					Rabbit
	lsotype:	procollagen-lysine, 2-o	l oglutarate 5-	F/ICC 1:50-1:500	
	lgG	dioxygenase 2			
	Immunogen Catalog Number: AG15614	Calculated MW: 758 aa, 85 kDa			
		Observed MW: 87 kDa			
	Applications	Tested Applications:	Positive Controls:		
Cited Applications: cells, H			o-2 cells, A431 cells, DU 145 cells, HT-1080 K-293 cells, HeLa cells, HepG2 cells		
WB, IHC, IF		1	P : mouse testi	s tissue,	
Species Specificity: human, mouse, rat		IHC : human liver cancer tissue, human pancreas			
Cited Species:		tissue, human s	aan skeletal muscle tissue		
human, mouse, rabbit, zebrafish				lls,	
TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0					
	buffer pH 6.0				
Background Information	PLOD2, also named as LH2, forms hyd novel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumouu of antiangiogenic treatment for mali and seven glycosylation sites. This ar	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155)	nong the PLOD at PLOD2 expre LOD2 expression . It has 2 isofor	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effe	
	PLOD2, also named as LH2, forms hyo novel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumou of antiangiogenic treatment for mali and seven glycosylation sites. This ar	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155)	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effe	
	PLOD2, also named as LH2, forms hydroprognostic factor for HCC patier prognosis and angiogenesis. Several information about malignant tumour of antiangiogenic treatment for mali and seven glycosylation sites. This are Author Pu	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) tibody is specific to PLOI	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effe ms produced by alternative splicing	
	PLOD2, also named as LH2, forms hydrowel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumour of antiangiogenic treatment for mali and seven glycosylation sites. This are Author Put Tomoaki Saito 34	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) htibody is specific to PLOI bmed ID Journal 718219 Bone	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effe ms produced by alternative splicing Application WB,IHC	
	PLOD2,also named as LH2, forms hydrophydron ar angiogenesis. Several information about malignant tumour of antiangiogenic treatment for maliand seven glycosylation sites. This ar Author Put Tomoaki Saito 34 Ryunosuke Nozaki 34	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) htibody is specific to PLOI bmed ID Journal 718219 Bone	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effe ms produced by alternative splicing Application WB,IHC	
	PLOD2,also named as LH2, forms hydrophydron ar angiogenesis. Several information about malignant tumour of antiangiogenic treatment for maliand seven glycosylation sites. This ar Author Put Tomoaki Saito 34 Ryunosuke Nozaki 34	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) tibody is specific to PLOI bmed ID Journal 718219 Bone 875533 Biocher	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effer ns produced by alternative splicing Application WB,IHC Commun WB	
Notable Publications	PLOD2,also named as LH2, forms hydrowel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumour of antiangiogenic treatment for malia and seven glycosylation sites. This are any seven glycosylatextra seven glycosylation sites. This are any seven gl	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) tibody is specific to PLOI bmed ID Journal 718219 Bone 875533 Biocher 898103 Sci Rep	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effer ns produced by alternative splicing Application WB,IHC Commun WB	
Notable Publications	PLOD2, also named as LH2, forms hydrovel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumour of antiangiogenic treatment for mali and seven glycosylation sites. This are Author Put Tomoaki Saito 34 Ryunosuke Nozaki 34 Bernd Stratmann 27 Storage: Store at -20°C. Stable for one year after Store at -20°C. Stable for one year after	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) tibody is specific to PLOI bmed ID Journal 718219 Bone 875533 Biocher 898103 Sci Rep er shipment.	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effer ns produced by alternative splicing Application WB,IHC Commun WB	
Background Information Notable Publications Storage	PLOD2,also named as LH2, forms hyc novel prognostic factor for HCC patie prognosis and angiogenesis. Several information about malignant tumour of antiangiogenic treatment for mali and seven glycosylation sites.This ar Author Put Tomoaki Saito 34 Bernd Stratmann 27 Storage: Storage Buffer: PBS with 0.02% sodium azide and 50	nts following surgery. An authors have reported th s such as glioblastoma. P gnancy. (PMID:22098155) tibody is specific to PLOI bmed ID Journal 718219 Bone 875533 Biocher 898103 Sci Rep er shipment.	nong the PLOD at PLOD2 expre LOD2 expression I thas 2 isofor D2.	genes, PLOD2 contributes to cancer ssion might provide prognostic on is a useful biomarker for the effer ns produced by alternative splicing Application WB,IHC Commun WB	


For technical support and original validation data for this product please contact:T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free
in USA), or 1(312) 455-8498 (outside USA)E: proteintech@ptglab.comW: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




WB result of PLOD2-Specific antibody (21214-1-AP; 1:1000; incubated at room temperature for 1.5 hours) with sh-Control and sh-PLOD2-Specific transfected A431 cells.



WB result of PLOD2-Specific antibody (21214-1-AP 1:3000; room temperature for 1.5 hours) with wildtype and PLOD2 knockout THLE-2 cells.




Various lysates were subjected to SDS PAGE followed by western blot with 21214-1-AP (PLOD2-Specific antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.




DU 145 cells lysates were subjected to SDS PAGE followed by western blot with 21214-1-AP (PLOD2-Specific antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.




Immunofluorescent analysis of (-20°C Methanol) fixed HeLa cells using PLOD2-Specific antibody (21214-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+1).




IP result of anti-PLOD2-Specific (IP:21214-1-AP, 4ug; Detection:21214-1-AP 1:500) with mouse testis tissue lysate 5000ug.





Immunohistochemical analysis of paraffinembedded human liver cancer tissue slide using 21214-1-AP (PLOD2-Specific antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

Immunohistochemical analysis of paraffinembedded human liver cancer tissue slide using 21214-1-AP (PLOD2-Specific antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human PLOD2-Specific (21214-1-AP) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug x. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).